lenalidomide has been researched along with cc 3052 in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (cc 3052) | Trials (cc 3052) | Recent Studies (post-2010) (cc 3052) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 8 | 1 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D | 1 |
1 trial(s) available for lenalidomide and cc 3052
| Article | Year |
|---|---|
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha | 2002 |